These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34196384)

  • 1. Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient.
    Kagohashi K; Miyazaki K; Shiozawa T; Satoh H
    Adv Respir Med; 2021; 89(3):316-319. PubMed ID: 34196384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.
    Gobbini E; Toffart AC; Pérol M; Assié JB; Duruisseaux M; Coupez D; Dubos C; Westeel V; Delaunay M; Guisier F; Veillon R; Gounant V; Giroux Leprieur E; Vanel FR; Chaabane N; Dansin E; Babey H; Decroisette C; Barlesi F; Daniel C; Fournel P; Mezquita L; Oulkhouir Y; Canellas A; Duchemann B; Molinier O; Alcazer V; Moro-Sibilot D; Levra MG
    Clin Lung Cancer; 2020 Sep; 21(5):e497-e510. PubMed ID: 32605892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Lin G; Wang Z; Chu Q; Hu Y; Huang D; Wang J; Yang F; Zhong W; Zhou C; Zhu B; Ai X; Cao B; Cao Y; Chen M; Chen X; Chu T; Duan J; Fan Y; Fang Y; Feng S; Feng W; Guo H; Han C; He Y; Hong S; Hu J; Huang M; Huang Y; Jiang D; Jiang K; Jiang R; Jin B; Jin S; Li J; Li M; Li Z; Li C; Lin J; Liu A; Liu SM; Yutao L; Liu Z; Liu Z; Liu Z; Liu Z; Liu Z; Lu Y; Lv T; Ma Z; Miao Q; Peng M; Pu X; Ren XB; Shan J; Shan J; Shen P; Shen B; Shi M; Song Y; Song Z; Su C; Sun J; Tian P; Wang J; Wang F; Wang H; Wang J; Wang Q; Wang W; Wang Y; Wu L; Wu F; Xia Y; Xie C; Xie C; Xin T; Xiong J; Xu H; Xu S; Xu Y; Xu B; Xu C; Yan X; Yang Z; Yao W; Yu Y; Feng Y; Yu Z; Yu Y; Yue D; Zhang H; Zhang H; Zhang L; Zhang L; Zhang Q; Zhang T; Zhang B; Zhao J; Zhao M; Zheng X; Zhong Q; Zhou J; Zhou P; Zhu Z; Zou J; Zou Z
    Thorac Cancer; 2024 Feb; 15(5):419-426. PubMed ID: 38219795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions.
    Gang X; Yan J; Li X; Shi S; Xu L; Liu R; Cai L; Li H; Zhao M
    Cancer Lett; 2024 Nov; 604():217241. PubMed ID: 39260670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.
    Gonugunta AS; von Itzstein MS; Gerber DE
    J Med Case Rep; 2022 Jul; 16(1):289. PubMed ID: 35871685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
    Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
    Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report.
    Guaitoli G; Barbieri F; Barbolini M; Molinaro E; Emidio KD; Borghi V; Dominici M; Bertolini F
    Immunotherapy; 2021 Mar; 13(4):277-281. PubMed ID: 33249929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between time to treatment failure and peripheral eosinophils in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
    Osawa H; Shiozawa T; Okauchi S; Miyazaki K; Kodama T; Kagohashi K; Nakamura R; Satoh H; Hizawa N
    Pol Arch Intern Med; 2021 Oct; 131(10):. PubMed ID: 34180611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: A case report.
    Zhang QN; Li Y; Zhao Q; Tian M; Chen LL; Miao LY; Zhou YJ
    Thorac Cancer; 2021 May; 12(10):1617-1619. PubMed ID: 33760389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
    Sherman S; Rotem O; Shochat T; Zer A; Moore A; Dudnik E
    Lung Cancer; 2020 May; 143():40-46. PubMed ID: 32203769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma].
    Wang X; Zhao Y; Chen Z
    Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):389-394. PubMed ID: 31196374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute kidney injury in patients treated with immune checkpoint inhibitors.
    Gupta S; Short SAP; Sise ME; Prosek JM; Madhavan SM; Soler MJ; Ostermann M; Herrmann SM; Abudayyeh A; Anand S; Glezerman I; Motwani SS; Murakami N; Wanchoo R; Ortiz-Melo DI; Rashidi A; Sprangers B; Aggarwal V; Malik AB; Loew S; Carlos CA; Chang WT; Beckerman P; Mithani Z; Shah CV; Renaghan AD; Seigneux S; Campedel L; Kitchlu A; Shin DS; Rangarajan S; Deshpande P; Coppock G; Eijgelsheim M; Seethapathy H; Lee MD; Strohbehn IA; Owen DH; Husain M; Garcia-Carro C; Bermejo S; Lumlertgul N; Seylanova N; Flanders L; Isik B; Mamlouk O; Lin JS; Garcia P; Kaghazchi A; Khanin Y; Kansal SK; Wauters E; Chandra S; Schmidt-Ott KM; Hsu RK; Tio MC; Sarvode Mothi S; Singh H; Schrag D; Jhaveri KD; Reynolds KL; Cortazar FB; Leaf DE;
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in Pseudoprogression of Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer].
    Tong Y; Long Y; Zhang F; Li J
    Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):306-320. PubMed ID: 38769834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
    Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.
    Takahara Y; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Sakuma T; Nishiki K; Nakase K; Nojiri M; Kato R; Shinomiya S; Fujimoto Y; Oikawa T; Mizuno S
    Thorac Cancer; 2022 Feb; 13(4):624-630. PubMed ID: 34989146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
    Okauchi S; Shiozawa T; Miyazaki K; Nishino K; Sasatani Y; Ohara G; Kagohashi K; Sato S; Kodama T; Satoh H; Hizawa N
    Pol Arch Intern Med; 2021 Feb; 131(2):152-160. PubMed ID: 33491942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.